MENU
+Compare
AKRO
Stock ticker: NASDAQ
AS OF
May 13, 11:56 AM (EDT)
Price
$41.48
Change
-$0.05 (-0.12%)
Capitalization
3.18B

AKRO Akero Therapeutics Forecast, Technical & Fundamental Analysis

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs... Show more

AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for AKRO with price predictions
May 12, 2025

AKRO's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for AKRO turned positive on April 17, 2025. Looking at past instances where AKRO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for AKRO crossed bullishly above the 50-day moving average on May 05, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AKRO advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 133 cases where AKRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AKRO moved out of overbought territory on May 02, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AKRO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

AKRO moved below its 50-day moving average on May 09, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKRO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKRO broke above its upper Bollinger Band on April 30, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.234) is normal, around the industry mean (14.767). P/E Ratio (0.000) is within average values for comparable stocks, (65.482). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.018). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (254.233).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

AKRO is expected to report earnings to rise 12.22% to -100 cents per share on August 08

Akero Therapeutics AKRO Stock Earnings Reports
Q2'25
Est.
$-1.01
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.17
Q3'24
Missed
by $0.17
Q2'24
Beat
by $0.02
The last earnings report on May 12 showed earnings per share of -89 cents, beating the estimate of -100 cents. With 132.74K shares outstanding, the current market capitalization sits at 3.18B.
A.I. Advisor
published General Information

General Information

a biotechnology company, which specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
601 Gateway Boulevard
Phone
+1 650 487-6488
Employees
56
Web
https://www.akerotx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APHYX24.250.65
+2.75%
Artisan Developing World Institutional
ABIAX16.07N/A
N/A
AB International Value A
GRGTX45.16N/A
N/A
Goldman Sachs Equity Income Inv
ANWFX63.26N/A
N/A
American Funds New Perspective F2
HMVRX15.86N/A
N/A
Hartford MidCap Value R3

AKRO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+4.22%
ETNB - AKRO
60%
Loosely correlated
+5.32%
SLS - AKRO
43%
Loosely correlated
-1.28%
TRDA - AKRO
40%
Loosely correlated
+5.25%
VTYX - AKRO
38%
Loosely correlated
-2.42%
MDGL - AKRO
37%
Loosely correlated
+2.08%
More